Reliance Life Sciences is building an integrated and global Biopharmaceutical initiative, through research, development and marketing of products in the categories of :

• Plasma Proteins


• Biosimilars (Recombinant Proteins and Monoclonal Antibodies)


• Novel Proteins

The company currently markets the following biopharmaceutical products in India and overseas markets:

• Plasma Proteins
• ReliSeal^® (Fibrin Sealants)
• AlbuRel™ (Albumin)
• ImmunoRel^® (Immunoglobulin)
• HemoRel^® (Anti-Hemophilic Factor)
• Biosimilars
• ReliFeron^® (Recombinant Interferon α)
• ReliPoietin™ (Recombinant Erythropoietin)
• ReliGrast^® (Recombinant Granulocyte colony stimulating factor)
• MIRel™ (Recombinant Reteplase - tissue plasminogen activator)
• FostiRel™ (Follicle stimulating hormone)
• ReliBeta™ (Recombinant Interferon beta-1a)
• ChorioRel™ (Recombinant chorionic gonadotrophin hormone r-hCG)

These products are manufactured in-house in cGMP facilities:

Plant 1 - Pilot scale facility for Plasma Proteins in Mumbai

Plant 2 - Commercial scale facility for Recombinant Proteins and Monoclonal Antibodies (mammalian and microbial cell culture and fill finish for vials and syringes) at Dhirubhai Ambani Life Sciences Center, Navi Mumbai

Plant 4A - Commercial scale facility for Plasma Fractionation at Dhirubhai Ambani Life Sciences Center, Navi Mumbai

Plant 4B - Commercial scale facility for Plasma Proteins at Dhirubhai Ambani Life Sciences Center, Navi Mumbai

These facilities conform to Indian FDA, WHO-GMP, EMEA and USFDA standards.

Reliance Life Sciences also offers Contract Manufacturing Services.in the areas of recombinant product manufacturing and fill-finish services (vials and syringes).

Reliance GeneMedix plc, a UK-based subsidiary of Reliance Life Sciences with a manufacturing facility in Ireland, is involved in developing biosimilars for the European market.

For more information please visit the website of GeneMedix at:
http://www.genemedix.com